Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 19,22 € (+4,29%). La mediana è 19,10 € (+3,64%).
| Acquista |
5 |
| Mantieni |
7 |
| Vendi |
1 |
Discussioni nella community
- Fehler: Dieses Portfolio ist privat
Hallo zusammen, ich komme seit ein paar Tagen nicht mehr in mein Portfolio. Nach dem einloggen sehen ich "Dieses Portfolio ist privat". Wenn ich dann auf den "zu deinem Portfolio" Button klicke…
PN Parqet Nutzer I in Schnack
0 45 - Spin-Off
Hallo, werden Spin-Offs automatisch verarbeitet, analog Split, oder muss man sie manuell hinzufügen?
user_9c1f0a I in Schnack 1 7
Notizie Vai al feed delle notizie
Viatris raises guidance after Q2 growth and gains FDA approval for contraceptive patch
Viatris reported Q2 revenue up about 4.9% year over year and management raised fiscal 2026 guidance across key metrics. Billionaire-led funds held stakes in the stock as it traded near $16, up ~33% year-to-date. The FDA approved the once-weekly Gwyn Lo contraceptive patch, a fast-acting meloxicam formulation is under review and two late-stage trials (selatogrel and cenerimod) will report in early fiscal 2027. Valuation looks attractive (forward non-GAAP P/E ~6.6, EV/EBITDA ~7) but tariff risk and looming changes to generic exemptions in 2028 pose material downside for its import-reliant portfolio. » Altro su finance.yahoo.com
Viatris beats Q2 expectations and raises full-year outlook
Viatris reported adjusted EPS of $0.69 for Q2 2026 (expectation $0.61) and revenue of $3.76 billion versus expected $3.67 billion, and subsequently raised its full-year guidance. Free cash flow and margins improved; adjusted EBITDA was $1.2 billion and gross margin rose to 57.5%. Debt fell to about 2.9x. The stock dipped slightly premarket as investors weighed potential H2 risks such as a new procurement policy in China, production interruptions in Nashik and intensified competition. » Altro su de.investing.com
Viatris receives FDA approval for once-weekly contraceptive patch Gwyn Lo
The FDA has approved Gwyn Lo, a once-weekly contraceptive patch from Viatris containing norelgestromin and ethinylestradiol. The patch is intended for women of childbearing potential with a BMI under 30 kg/m² and delivers 220 mcg norelgestromin and 20 mcg ethinylestradiol per day. Approval was based on the Phase III Luminous study, which showed a Pearl Index of 4.14 and complete detachment of only 1.3% of applied systems. Common side effects included application-site reactions, irregular and heavy withdrawal bleeding, and nausea; Gwyn Lo is contraindicated in smokers over 35 and in women with BMI ≥30 kg/m². Viatris expects to launch the product later this year. » Altro su de.investing.com
Viatris hits 52‑week high of $17.68 after strong quarterly results and Phase‑3 success
Viatris shares rose to a 52‑week high of $17.68, driven by strong price performance (+90.82% year‑to‑date) and a market capitalization of $20.6 billion. The company beat Q1‑2026 expectations with adjusted EPS of $0.59 (consensus $0.51) and revenue of $3.52 billion. Viatris also reported positive Phase‑3 results for the IgAN drug VR‑205 in Japan, and the FDA has accepted the approval filing for a rapid‑acting meloxicam formulation (PDUFA date 27.12.2026). InvestingPro rates the stock as undervalued; management has executed aggressive buybacks and expects to be profitable this year. » Altro su de.investing.com
Viatris hits 52-week high at $17.53 after strong results and study successes
Viatris shares rose to a new 52-week high of $17.53; market capitalization stands at $20.26 billion. Year-to-date the stock has climbed 41% and is up 94% over the past year. Viatris beat Q1 2026 analyst expectations with adjusted EPS of $0.59 and revenue of $3.52 billion. The company also reported positive Phase‑3 results for VR‑205 in Japan and the FDA has accepted the approval pathway for MR‑107A‑02 (PDUFA date 27.12.2026). According to InvestingPro, the calculated fair value indicates further upside potential. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 3,31 Mld | 3,32% |
| Utile lordo | 1,27 Mld | 7,58% |
| Utile netto | -287,19 Mln | 162,89% |
| EBITDA | 827,67 Mln | 21,38% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 21,63 Mld € |
Numero di azioni | 1,15 Mld |
Massimo/minimo a 52 settimane | 19,29 € - 9,23 € |
Rendimento da dividendo | 2,19% |
Dividendi TTM | 0,42 € |
Prossimo dividendo | 0,11 € |
Beta | 0,87 |
Rapporto P/E | -39,13 |
Rapporto PEG | 1,11 |
Rapporto P/B | 1,74 |
Rapporto P/S | 1,61 |
Profilo aziendale
Viatris Inc. opera come società sanitaria a livello mondiale. La società opera in quattro segmenti: Developed Markets, Greater China, JANZ ed Emerging Markets. Offre farmaci di marca con prescrizione, farmaci generici, farmaci generici complessi, biosimilari e principi attivi farmaceutici (API). La società offre farmaci in diverse aree terapeutiche, tra cui malattie non trasmissibili e malattie infettive; biosimilari nelle aree di oncologia, immunologia, endocrinologia, oftalmologia e dermatologia; e API per gli antibatterici, gli agenti del sistema nervoso centrale, gli antistaminici/antiasmatici, il cardiovascolare, gli antivirali, gli antidiabetici, gli antimicotici e gli inibitori di pompa protonica, nonché servizi di supporto, quali cliniche diagnostiche, seminari educativi e strumenti digitali per aiutare i pazienti a gestire meglio la propria salute. Fornisce i propri medicinali sotto forma di dosi solide orali, iniettabili, forme farmaceutiche complesse e API a farmacie al dettaglio e strutture di farmacia, grossisti e distributori, payer, assicuratori e governi, e istituzioni. La società distribuisce i propri prodotti tramite grossisti/distributori farmaceutici, farmacie al dettaglio, farmacie istituzionali, farmacie di vendita per corrispondenza ed e-commerce e farmacie specializzate. Vende i propri prodotti con i marchi Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, auto-iniettore EpiPen, Fraxiparine e Yupelri; Norvasc e Viagra; AMITIZA, Lipacreon ed Effexor; e Celebrex e ARV, e offre franchising di biosimilari, tra cui Fulphila, Ogivri, Hulio e SEMGLEE. La società ha accordi di collaborazione e licenza con Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; e Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. è stata fondata nel 1961 e ha sede a Canonsburg, Pennsylvania.
| Nome | VIATRIS INC. O.N. |
| CEO | Scott Andrew Smith |
| Sede centrale | Canonsburg,
pa Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 17/03/1980 |
| Dipendenti | 30.000 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | VTRS |
XETRA | VIA.DE |
Frankfurt | VIA.F |
Düsseldorf | VIA.DU |
Hamburg | VIA.HM |
Milan | 1VTRS.MI |
London | 0A5V.L |
München | VIA.MU |
Wien | VTRS.VI |
SIX | VTRS.SW |